Dignify Therapeutics Initiates Phase 1 Trial for Innovative Bowel Dysfunction Treatment

Dignify Therapeutics Begins Phase 1 Study of DTI-117 for Neurogenic Bowel Dysfunction



Dignify Therapeutics, a biopharmaceutical company dedicated to enhancing bowel and bladder control for individuals facing neurological challenges, has officially started its Phase 1 study on DTI-117, a promising on-demand treatment aimed at neurogenic bowel dysfunction (NBD). The initial dosing took place on November 17, 2026, marking a significant milestone in the development of this therapeutic intervention.

The ongoing study, recognized by the ClinicalTrials.gov identifier NCT07882472, operates as a randomized, double-blind, placebo-controlled trial. This approach is critical in evaluating the safety, tolerability, and pharmacokinetics of DTI-117. Funded by the National Institutes of Health (NIH), the study will engage up to 40 participants across various ascending dose cohorts, allowing researchers to ascertain the appropriate levels of DTI-117 for future therapeutic use. Participants will be randomly assigned to receive either DTI-117 or a placebo, ensuring that the data collected is robust and reliable. Preliminary topline data from these initial cohorts is expected to be available in early 2027.

Neurogenic bowel dysfunction often complicates the everyday lives of those affected, creating challenges in self-management. Many individuals experience difficulties in achieving bowel evacuation independently, leading to excessive reliance on caregivers. Current solutions, like laxatives, enemas, and manual evacuation, can be unpredictable and sometimes stigmatizing. DTI-117 aims to provide patients with greater control over their bowel function. Dr. Karl Thor, Chief Scientific Officer at Dignify, emphasized this perspective, stating, "DTI-117 is designed to return control of timing to the person who needs it."

The underlying philosophy of Dignify Therapeutics focuses on empowering individuals affected by neurological conditions. Anthony DiTonno, the company's CEO, expressed commitment to this mission by stating, "Dignify was founded on the belief that people with neurological conditions should be able to decide when they empty their bowel and bladder." With the first participant now dosed, the company looks forward to evaluating the efficacy of DTI-117 in real-world scenarios.

About DTI-117


DTI-117 is classified as a novel, short-acting peptide and neurokinin-2 receptor agonist, specifically engineered for the treatment of neurogenic bowel dysfunction and related disorders of bladder and bowel voiding. This investigational drug is meticulously designed to induce rapid and transient bowel emptying while allowing the patient to control the timing of this process. With the clearance of IND, DTI-117 is undergoing an NI-funded trial featuring a randomized, double-blind, placebo-controlled approach. Early results from this study are highly anticipated by both medical professionals and patients alike.

About Dignify Therapeutics


Founded by a dynamic team of experienced entrepreneurs and renowned scientists, Dignify aims to develop practical solutions for bladder and bowel voiding dysfunction, particularly among individuals with neurogenic conditions. The company benefits from various support mechanisms, including considerable financial backing from venture capital sources, state programs, and significant NIH funding, amounting to over $20 million across 18 different awards. Dignify Therapeutics operates from the First Flight Venture Center in Research Triangle Park, North Carolina, with its development efforts guided by research from the National Institute of Neurological Disorders and Stroke, NIH under Award Number U44NS129628.

The initiative to advance DTI-117 paves the way for a transformative approach to managing neurogenic bowel dysfunction, a condition that profoundly impacts the patients' quality of life. As Dignify Therapeutics progresses with its clinical trials, the results promise to shed light on a new frontier in therapeutic options, potentially improving the lives of countless individuals.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.